Search Articles
MANHATTAN – Sanofi issued contingent value rights at inflated prices when it acquired codefendant Genzyme, and the CVRs fell by 62 percent when misleading statements about the MS drug Lemtrada were revealed, investors claim in Federal Court.
Categories /
Uncategorized
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.